These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3162176)

  • 61. Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.
    Johansen TE; Ogreid P; Kjellevold K; Blom P
    Br J Urol; 1990 Apr; 65(4):376-8. PubMed ID: 2140282
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer.
    Røhl HF; Beuke HP
    Scand J Urol Nephrol; 1992; 26(1):11-4. PubMed ID: 1631501
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gonadotrophin-releasing hormone analogue agonists--a new approach in advanced prostatic cancer.
    Thürlimann BJ; Falkson G
    S Afr Med J; 1985 Dec; 68(12):888-9. PubMed ID: 3906944
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of prostatic cancer with LH-RH analogues.
    Borgmann V; Nagel R; Al-Abadi H; Schmidt-Gollwitzer M
    Prostate; 1983; 4(6):553-68. PubMed ID: 6415628
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
    González-Bárcena D; Pérez-Sánchez P; Hernández-Meza AR; Rangel-García N; Graef-Sánchez A; Comaru-Schally AM; Schally AV
    Arch Invest Med (Mex); 1987; 18(4):273-8. PubMed ID: 2969222
    [No Abstract]   [Full Text] [Related]  

  • 66. [Treatment of advanced prostate carcinoma with a depot form of an LH-RH analog: preliminary endocrinological and clinical results].
    Litjens TT; Fernandez del Moral P; van Laarhoven JP; Weil EH; Debruyne FM
    Ned Tijdschr Geneeskd; 1986 Apr; 130(17):787-90. PubMed ID: 3086754
    [No Abstract]   [Full Text] [Related]  

  • 67. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma.
    Koutsilieris M; Tolis G
    Prostate; 1983; 4(6):569-77. PubMed ID: 6415629
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The treatment of prostatic cancer by LH-RH agonist.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I
    Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552
    [No Abstract]   [Full Text] [Related]  

  • 69. Gonadotropin-releasing hormone analogs and prostatic cancer.
    Swanson LJ; Seely JH; Garnick MB
    Crit Rev Oncol Hematol; 1988; 8(1):1-26. PubMed ID: 2964939
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy.
    De Sy WA; De Wilde P; De Meyer JM; Casselman J; Desmet R; Renders G; Schelfhout W
    Acta Urol Belg; 1988; 56(4):581-8. PubMed ID: 2974680
    [No Abstract]   [Full Text] [Related]  

  • 71. A man with hypogonadotropic hypogonadism successfully treated with nasal administration of the low-dose gonadotropin-releasing hormone analog buserelin.
    Iwamoto H; Yoshida A; Suzuki H; Tanaka M; Watanabe N; Nakamura T
    Fertil Steril; 2009 Sep; 92(3):1169.e1-1169.e3. PubMed ID: 19591988
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical development of nafarelin acetate. Phase I and phase II studies.
    Hoffman PG; Henzl MR; Chaplin MD; Nerenberg CA
    J Androl; 1987; 8(1):S17-22. PubMed ID: 2951357
    [No Abstract]   [Full Text] [Related]  

  • 73. Intranasal buserelin in the treatment of advanced prostatic cancer: a phase II trial.
    Falkson G; Vorobiof DA
    J Clin Oncol; 1987 Sep; 5(9):1419-23. PubMed ID: 3114438
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Therapeutic use of a gonadotropin releasing hormone analogue in breast cancer].
    Kahán Z; Falkay G
    Orv Hetil; 1990 May; 131(19):1033-6. PubMed ID: 2111904
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
    Blom JH; Hirdes WH; Schröder FH; de Jong FH; Kwekkeboom DJ; van't Veen AJ; Sandow J; Krauss B
    Urol Res; 1989; 17(1):43-6. PubMed ID: 2493705
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Three-monthly GnRH agonist (buserelin) for prostatic cancer.
    Waxman J; Sandow J; Abel P; Barton C; Keane P; Williams G
    Br J Urol; 1990 Jan; 65(1):43-5. PubMed ID: 2107012
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1985; 7(1):21-30. PubMed ID: 2934692
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 79. Establishing an Animal Model of Secondary Osteoporosis by Using a Gonadotropin-releasing Hormone Agonist.
    Mohamad NV; Che Zulkepli MAA; May Theseira K; Zulkifli N; Shahrom NQ; Ridzuan NAM; Jamil NA; Soelaiman IN; Chin KY
    Int J Med Sci; 2018; 15(4):300-308. PubMed ID: 29511366
    [No Abstract]   [Full Text] [Related]  

  • 80. [Treatment of metastatic cancer of the prostate with LH-RH agonists].
    Zungri E; Chechile G; Díaz I; Sarroca J; Valdes L; Mallo N
    Actas Urol Esp; 1986; 10(3):171-6. PubMed ID: 3090862
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.